Novel coronavirus pneumonia sample pre test study received ethical approval

On February 10, guangshengtang announced that, Novel coronavirus infection was also a major technical consideration In January 31, 2020, the experts of the center for drug evaluation organized a number of technical experts and Guangshen Tang development team to convene a technical seminar on the above new antiviral drugs and generic drugs for the treatment of new coronavirus infected patients with pneumonia, and made specific and specific research directions for the projects The company recommended that GST-HG131 and GST-HG121 be used as new anti coronavirus as soon as possible Novel coronavirus pharmacodynamics data of the virus and pharmacodynamics of generic drugs used for anti novel coronavirus were presented, and the research data were submitted as soon as possible In February 6, 2020, novel coronavirus was submitted to the Concord Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, the two core generic drug approved by G2 and G3 for the treatment of new coronavirus pneumonia In February 7, 2020, the novel coronavirus, a small sample pre test study of pneumonia induced by mild or moderate coronavirus infection, was launched by researchers in the clinical "G2 or G3 generic drug".